Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EWPI .39 x .40 (1x3) not to shabby!
EWPI low floater up nicely on 62K
EWPI headin for .50+
Again you missed my alert this morning (: I would like to know where the heck you party? :)
MONSTER bounce is RIGHT!!!!!
Nice to see more participants on AMSZ today!
Yes, HBRM!
I think EWPI has the goods to get back up over the .50's
MHTX .09 +28 points, company looks solid from here on!
You back in from your entertaining? LOL
Looks like the volume is starting to dry up a bit.
Suetta....always a pleasure to share with you....MHTX ACRI EWPI!
PRAN will spike back up again, MHTX picking up!
MHTX .094 +34% nes below:
Manhattan Scientifics’ Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram
2010-04-21 10:10 ET - News Release
New Technology 100% Radiation Free
Company Website: http://www.mhtx.com/
ALBUQUERQUE, N.M. -- (Business Wire)
Manhattan Scientifics, Inc. (OTCBB: MHTX) announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nano medicine.
When fully developed and commercialized, Dr. Flynn's biomagnetic-based system will be 100% radiation free, unlike current radiation-based mammogram tests. Manhattan Scientifics is currently seeking a partner to commercialize the technology.
To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventive Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits...." according to an article published by Bloomberg News, November 17, 2009.
CEO Manny Tsoupanarias said, "We believe early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn’s technology has proven the ability to detect breast cancer tumors only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection.
“The new technology has demonstrated similar early detection performance for ovarian cancer, a cancer that currently has no effective screening techniques. Our technology also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn’s work has been supported for eight years by nine grants from the National Institutes of Health and a grant from the U.S. Department of Defense. The technology is protected by issued and pending patents,” Tsoupanarias said.
Dr. Flynn said, “Our approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. This method yields high contrast images of tumors compared to normal cells. With this biomagnetic imaging technique, it is possible to identify and image tiny clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible. This has a distinct advantage over other imaging methods in that it detects only particles bound to targeted cells and is not sensitive to unbound particles where other methods may be overwhelmed by the unbound particles. It is done without the use of ionizing radiation. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate and potentially to many other cancers.”
Tsoupanarias added, “As an inventions company, our strategy is to partner with large, well financed, experienced manufacturers and marketers. Manhattan Scientifics typically receives royalty income and fixed fees from its industrial partner. Our new class of metals nano-technology business is a clear and profitable example of our business model. We have a long way to go with our early cancer technology, but we are excited about the obvious prospects, both for the overall improvement of early cancer detection as well as for our own business.”
On February 25, 2010, Manhattan Scientifics announced that it had acquired exclusive rights to commercialize Dr. Flynn's work.
Your welcome, AMSZ, ACRI MHTX...EWPI (radar her for a little pop imo).
Take a look at MHTX news release today, if Therma can get its self going!!!!!!
MHTX gearing up, .10 +43% news below:
Manhattan Scientifics’ Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram
2010-04-21 10:10 ET - News Release
New Technology 100% Radiation Free
Company Website: http://www.mhtx.com/
ALBUQUERQUE, N.M. -- (Business Wire)
Manhattan Scientifics, Inc. (OTCBB: MHTX) announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nano medicine.
When fully developed and commercialized, Dr. Flynn's biomagnetic-based system will be 100% radiation free, unlike current radiation-based mammogram tests. Manhattan Scientifics is currently seeking a partner to commercialize the technology.
To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventive Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits...." according to an article published by Bloomberg News, November 17, 2009.
CEO Manny Tsoupanarias said, "We believe early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn’s technology has proven the ability to detect breast cancer tumors only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection.
“The new technology has demonstrated similar early detection performance for ovarian cancer, a cancer that currently has no effective screening techniques. Our technology also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn’s work has been supported for eight years by nine grants from the National Institutes of Health and a grant from the U.S. Department of Defense. The technology is protected by issued and pending patents,” Tsoupanarias said.
Dr. Flynn said, “Our approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. This method yields high contrast images of tumors compared to normal cells. With this biomagnetic imaging technique, it is possible to identify and image tiny clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible. This has a distinct advantage over other imaging methods in that it detects only particles bound to targeted cells and is not sensitive to unbound particles where other methods may be overwhelmed by the unbound particles. It is done without the use of ionizing radiation. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate and potentially to many other cancers.”
Tsoupanarias added, “As an inventions company, our strategy is to partner with large, well financed, experienced manufacturers and marketers. Manhattan Scientifics typically receives royalty income and fixed fees from its industrial partner. Our new class of metals nano-technology business is a clear and profitable example of our business model. We have a long way to go with our early cancer technology, but we are excited about the obvious prospects, both for the overall improvement of early cancer detection as well as for our own business.”
On February 25, 2010, Manhattan Scientifics announced that it had acquired exclusive rights to commercialize Dr. Flynn's work.
Hope all is well!!!!!
MHTX, news out, starting up !!!!!!
EWPI ask falling on little volume!
They should be generating some revs from the clinic, they should be disclosing that filing soon!
Morning, AMSZ looking sweet!
ACRI .074 +81% looking sweet!
Who turns down $26M....Don't you have any pull over at the US State Dept?
Gotta ride the financials, markets will be going much higher from here!
ACRI .08's back up next!
Good morning, ACRI on the go!
We might see a record volume day if she fires up!
PRAN....SMOKER!!!!!!
PRAN 1.35 lod now at 3.18 +135% on news!!!
Now getting the Gold out of the ground....do we have enough shoves for everyone here?
Heard from a number of T/A's that attended the annual TA conference last year, that it was talked about having companies to trade above .01 mark as part of the requirements. How and when are they going to do that (if its implemented), is anyones guess.
Stranded John Cleese takes US$5,100 cab ride from Oslo to Brussels
Monty Python comedy legend John Cleese took a US$5,100 dollar taxi ride from Oslo to Brussels after becoming stranded in Europe’s volcanic ash travel crisis, the Norwegian TV2 broadcaster reported on Friday.
“We checked every option, but there were no boats and no train tickets available. That’s when my fabulous assistant determined the easiest thing would be to take a taxi,” Mr. Cleese told the broadcaster in a telephone interview posted on its website in Norwegian.
The bill? A whopping US$5,100, said Mr. Cleese, who was visiting the Norwegian capital to take part in the popular Scandinavian talk show Skavlan.
SEC/Pinksheets are tightening up on these CEO's....say goodbye to under a penny stocks in the near future imo!
Good morning VZ3....how was your weekend? Were you glued to hockey or basketball screens?
I would like to see a "more-indepth" analysis of the assay results!
She needs to somehow repair itself!
You may want to look at PRAN, fairly good news imo!
PRAN (1.75 +29%) New Analysis of Prana's Clinical Trial Is Published in the Journal of Alzheimer's Disease
2010-04-19 11:00 ET - News Release
NEW YORK, NY -- (MARKET WIRE) -- 04/19/10
Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the authoritative scientific journal, Journal of Alzheimer's Disease, published an article on April 19 about Prana's lead drug candidate for Alzheimer's disease, PBT2, providing new analysis that it is effective in reversing dementia symptoms. The analysis, conducted by Professor Ashley Bush of The Mental Health Research Institute and The University of Melbourne, Australia, is based on tracking and ranking the responses of each individual patient, rather than only groups of patients, in Prana's PBT2's Phase IIa Alzheimer's disease clinical trial.
The results of the Phase IIa clinical trial, previously reported in The Lancet Neurology (July 2008 and an erratum in July 2009), showed that patients with mild Alzheimer's Disease treated with 250mg of PBT2, experienced an overall statistically significant improvement in Executive Function on a Neuropsychological Test Battery (NTB) within 12 weeks of treatment.
"Improvements in Executive Function is strongly related to improvement in daily function and to the quality of the daily life of patients," noted Dr. Jeffrey Cummings, Director, Alzheimer Disease Research Center, UCLA, and Chairman of Prana's Scientific Advisory Board.
"Very few drugs in clinical development have been able to bring these benefits to Alzheimer's Disease patients. I am very encouraged by these findings," concluded Dr. Cummings.
The Journal of Alzheimer's Disease paper reports the results of a post-unblinding analysis of the cognitive data that was not included in the original paper. The objective of the analysis was to see how individual patients who were receiving PBT2 responded compared to the individual patients who only received placebo. Importantly, even placebo patients showed some improvement in the tests because of a 'learning effect' of repeated testing. This new analysis has adjusted for this and demonstrated that:
81% of patients on the 250mg dose of PBT2 responded better on the Executive Factor NTB score than the best performing patient on placebo.
41% of patients on the 250mg dose of PBT2 responded better on the overall Composite NTB score than the best performing patient on placebo (of which Executive Function is one of 2 parts).
Asking the specific question, 'What is the probability that any patient who showed cognitive improvement was receiving PBT2?,' the paper reports there was a significant probability that:
Patients who improved in Executive Function were probably receiving 250mg of PBT2 (p=1.3 x 10-(9))
Patients who improved their Composite NTB were probably receiving 250mg of PBT2 (p=.0007)
Improvement in ADAS-Cog, a measure of memory and cognition, almost achieved a statistically significant level in the 12 week trial. Patients who improved their ADAS-Cog score were probably receiving 250mg of PBT2 (p=.056).
Professor Colin Masters of the Mental Health Research Institute and internationally acknowledged leader in Alzheimer's Disease research, commented that: "These results are very exciting given that they were achieved in mild Alzheimer's Disease sufferers in a relatively short period of time. Based on clinical trial outcomes to date, Prana's therapeutic strategy stands up as one of the safest and most effective means of treating the disease."
PBT2 targets the pathological interaction between A-beta and synaptic metal ions to prevent downstream toxic A-beta oligomer formation. PBT2 can also transfer metal ions otherwise trapped by A-beta oligomers into neurons, helping to promote normal memory function.
PRAN news just released, check her out!